PALISADE BIO, INC. cotiza a 1.47 USD y tiene una capitalización bursátil de $256M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat pati…
| Periodo | 2026-08 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-0.05 | $-0.38 | $-0.58 | $-0.47 |
| Estimado | $-0.05 | $-0.27 | $-0.56 | $-0.81 |
| Sorpresa | +0.0% | -40.7% | -3.6% | +42.0% |
| Métrica | PALI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -13.0% | -40.4% | +27.4% |
| ROA | -12.5% | -32.0% | +19.5% |
| Current Ratio | 28.95 | 2.84 | +26.11 |
| Debt / Equity | — | 0.28 | — |